JOHN A. HOUSTON, District Judge.
Pending before the Court is Plaintiff Spectrum Laboratories, LLC's ("Plaintiff") motion for enhanced damages, attorneys' fees, and prejudgment interest. Doc. No. 336. Defendants Dr. Greens Inc. and Matthew Green (collectively "Defendants") filed an opposition to the motion. Doc. No. 337. The motion is fully briefed. After careful review of the pleadings filed by both parties, and for the reasons set forth below, the Court
On February 23, 2018, a jury verdict was entered in favor of Plaintiff and against Defendants. Doc. No. 326. The jury found Defendants liable for direct infringement, indirect infringement, and contributory infringement for multiple products.
Pursuant to section 284 of the 1952 Patent Act, "[u]pon finding for the claimant the court shall award the claimant damages adequate to compensate for the infringement, but in no event less than a reasonable royalty for the use made of the invention by the infringer." 35 U.S.C. § 284. "Damages is the amount of loss to a patentee . . . A patentee may seek to recover actual damages, usually, the amount of profits actually lost, or if unable to prove actual damages, the patentee is entitled to a reasonable royalty."
The decision to award enhanced damages is committed to the sole discretion of the trial judge.
Plaintiff argues that Defendants failed to investigate the scope of Plaintiff's '776 patent. Doc. No. 336-1 at pg. 3. Specifically, Plaintiff contends that despite being twice sued by Defendant for infringement, Defendants did not form a good faith non-infringement belief.
In response, Defendants assert that they did not deliberately copy Plaintiff's ideas or design. Doc. No. 337 at pgs. 3-4. Defendants contend that they investigated the scope of Plaintiff's patent, determined Plaintiff's '776 patent was invalid, and proceeded in good faith.
In patent cases, courts can award enhanced damages when there is willful misconduct.
Defendants were Plaintiff's largest distributor of Plaintiff's Quick Fix formulation and '776 patent products. Defendants knew Plaintiff held the '776 patent from the time it issued in March of 2007, and knew that Plaintiff's Quick Fix was created a few months before the '786 patent was filed. Doc. 312 at pg. 31; Doc. No. 318 at pg. 24. Defendants profited handsomely as a result of the business relationship with Plaintiff. Doc. No. 313 at pg. 185.
Armed with this knowledge, Defendants developed its infringing product, Agent X. In developing its product, Defendants did not investigate the '776 patent to obtain a good faith belief that Agent X was not infringing. Defendants did not obtain a legal opinion to determine whether its product infringed (Doc. No. 320 at pgs. 160-63) and did not perform independent chemical testing of Agent X to determine whether it included one of the infringing biocides. Doc. No. 318 at pgs. 29-32. Defendants never obtained the formula from its supplier, never informed its supplier about the existence of '776, and the supplier did not test its own formula to determine whether it included one of the infringing biocides. Doc. No. 318 at pgs. 29-32, 59-60. Notwithstanding, Defendants began selling Agent X, alongside Quick Fix and '776 products, directly competing against Plaintiff's products. Doc. No. 320 at pg. 179.
After receiving cease and desist warnings from Plaintiff, Defendants sold its infringing product for four years and, during that time, did not pursue a non-infringing alternative. Defendants proceeded to file the first of two infringement-related lawsuits against Plaintiff. The first case was dismissed without prejudice. Thereafter, Defendants filed its second action on March 29, 2011 asserting non-infringement. Defendants then sold off their existing Agent X product and failed to maintain any samples of the old Agent X. See Doc. No. 318 at pgs. 38-41. Defendants also secretly changed suppliers and formulas in 2011 without advising Plaintiff or the Court, and demonstrated willfulness in infringing by covering up the infringing activity in its effort to deceive Plaintiff as to the nature of its infringing product. Defendants committed these acts in lieu of undertaking any remedial action. These actions support motivation to harm, willful misconduct, and evidence of guilt. The jury's finding of willfulness was supported by the evidence.
For these reasons and other reasons stated below, the Court finds that Defendants' willful infringement amounts to "egregious infringement behavior."
Plaintiff also argues that it is entitled to reasonable attorneys' fees. Doc. No. 336-1 at pgs. 10-11. Plaintiff largely makes the same arguments for attorneys' fees that it makes for enhanced damages, contending that this case is `exceptional' and thus qualifies for attorneys' fees.
Willful infringement by Defendants may support a finding that this case is "exceptional" within the meaning of 35 U.S.C. § 285. See
In this case, the record is replete with many pretrial disputes between the parties involving Defendants' discovery avoidance tactics and charging decisions, increasing litigation costs. Defendants postponed the litigation by refusing to identify its supplier, a tactic permitting the supplier to sell off its remaining supply of Agent X. Defendants' behind the scene sell-off was not known to Plaintiff or the Court. Plaintiff did not learn that the supply was sold off until after the Court granted Plaintiff's motion to compel.
Thereafter, issues relating to Defendants' noticing of experts increased litigation and were concerning to the Court. Defendants noticed an expert, knowing that expert was previously contacted and engaged by Plaintiff, and later failed to timely notice another expert. Defendants explained away the lack of timely designation of its expert with inconsistent excuses, ranging from staff issues and inconsistent pre-trial orders to ultimately designating the particular expert as a rebuttal expert. See, e.g. Doc. No. 166 at pgs. 2-6. There were also conflicting assertions related to timing of service of contentions which Plaintiff asserted were not received, thereby causing Plaintiff and the Court to expend significant resources to obtain a handle on these moving goal posts.
While the Court initially ruled in Defendants' favor on some of these matters, Defendants' discovery abuses and pre-trial strategy ultimately caused this Court to re-focus on the underpinnings of the disputes. Defendants' litany of excuses for non-production of documents and its pretrial strategies resulted in this Court's findings resolving on-going discovery disputes in favor of Plaintiff, (
Another example of pretrial misconduct occurred prior to a scheduled settlement conference. Plaintiff requested Defendants to stipulate to a telephonic settlement conference because its principals were out of district and the parties settlement discussions were acres apart. Defendants refused, representing to the magistrate judge that the parties were close to arriving at a settlement. On the day of the settlement conference with Plaintiff's principals present, Defendant Matthew Greens did not appear, preluding any meaningful settlement discussions. This tactic created enhanced legal and travel costs to Plaintiff.
Defendants filed five motions for summary judgment. The Court denied all but the infringement motion. The motions denied were brought without any reasonable merit. The Court agrees with Plaintiff that these motions stretched Plaintiff's legal resources and increased its cost of litigation. In addition, the Court denied Defendants' motions for sanctions, one of which concerned the alleged spoliation of an Agent X sample by Plaintiff's expert witness, even though Defendants sold off its own product and disregarded their responsibility to test and maintain samples to prove its case.
At trial, Defendants made a number of attempts to introduce evidence excluded in pre-trial proceedings and other inadmissible evidence, creating extended side bars, extending the number of trial days set aside for the trial, and impeding upon the time frame in which Plaintiff had to complete its case in chief, all to the detriment of Plaintiff. In addition, the evidence at trial demonstrated Defendants were and continued to be financially rewarded by its infringing conduct. Up to the day of trial, Defendants continued to sell Agent X and Plaintiff's product, producing substantial revenue. The evidence established that Defendants' earned millions of dollars earned in revenue per year. Their profit from the sale of Agent X represented 71% of total profit, and Defendants' profit from the sale of Plaintiff's product represented only 18% of total profit (Doc. No. 320 at pgs. 145, 182-83), further demonstrating the detrimental impact of Defendants' infringement on Plaintiff's bottom line.
The Court agrees with Plaintiff that this case is exceptional. In addition, the overwhelming strength of Spectrum's evidence presented at trial illuminated the underlying hidden purpose of Defendants' pretrial reasons for their litigation tactics that unreasonably and unfairly extended Plaintiff's litigation resources.
For these reasons, the Court finds attorneys' fees under 35 U.S.C. § 285 are warranted.
Plaintiff argues that, as the victorious patentee, it is entitled to a prejudgment interest award of $326,728. Doc. No. 336-1 at pgs. 11-12. Plaintiff asserts that $326,728, the prejudgment interest amount from 2007 through May 22, 2018, is based on prime interest rates reported by JPMorgan Chase.
In response, Defendants argue that Plaintiff contributed to the delay in litigation by not responding to Defendants' counterclaim and other letters. Doc. No. 337 at pg. 18. Defendants contend that Plaintiff's failure to respond caused a two year delay in the litigation.
The Court may award prejudgment interest when it "is necessary to ensure that the patent owner is placed in as good a position as it would have been had the infringer entered into a reasonable royalty agreement."
Based on the foregoing reasons, Plaintiff's motion for enhanced damages, attorneys' fees, and prejudgment interest is